Precision Medicine, Made Possible with Metabolomics
Traditionally, most medical interventions follow the one-size-fits-all approach, have been designed for a “typical” patient, and have been codified in treatment guidelines. Such strategies may be successful in some individuals while others will draw no benefit from them. By contrast, precision medicine considers differences in people’s genomes, environments, and lifestyles to tailor disease prevention and treatments. Thus, the most appropriate targeted therapy is delivered to the right patient at the correct time, which is the goal of precision medicine. Additionally, a patient’s ability to tolerate or respond to a therapeutic intervention (medicinal and nutritional) can be characterized and the information utilized to optimize the effects of these interventions. Despite continuous progress and many success stories, many in the field of oncology, broad implementation of precision medicine in practice is missing.
Human Disease Phenotypes are Very Complex
To deliver a precision medicine-based approach, one must be able to identify biomarkers associated with a specific disease phenotype. Deciphering genomes behind phenotypes is one way of identifying targets of interventions. However, the existence of a striking number of genetic variants, variable penetrance of known genetic variants, and polygenic etiologies make pinpointing relevant genetic abnormalities very difficult. Extra-genome (microbiome, epigenetics, environment, and lifestyle factors) influences on phenotypes also need to be considered.
Is there a relatively easy way of deconvoluting complex phenotypes underlain by multiple factors? Metabolomics may be the answer.
Metabolomics as an Enabling Tool in Precision Medicine
The metabolome comprises the complete set of small molecules (metabolites) present in the body. Metabolomics, the technology for surveying the metabolome, should be viewed as a high-resolution phenotyping method given that it appraises metabolites deriving from all physiological, pathological/endogenous, and exogenous processes that take place in an organism. Metabolites vary between health and disease and can act as disease biomarkers and characterize a patient’s response to treatment.
Metabolon provides tools to comprehensively study the metabolome and uses proprietary metabolomics technology that has been shown to be successful at detecting inborn errors of metabolism and rare diseases.
Potential Insights in Precision Medicine from Metabolomics
Metabolic signatures obtained via global metabolomics can provide predictive, prognostic, and diagnostic biomarkers, help dissect the underlying molecular mechanisms of diseases, study links between microbiota and the host organism, guide classification of diseases and stratification of patients, provide biomarkers of drug response, safety, and interactions (pharmacometabolomics) in clinical trials. It is hoped that metabolomics will help define a metabotype for each specific genotype, offering a functional read-out for the many genetic variants of unknown significance, and provide a way to monitor the remission/relapse status in chronic disease.
See how Metabolon can advance your path to preclinical and clinical insights
Metabolomics Panels for Precision Medicine
Amino Acids Targeted Panel
Beta-Hydroxybutyrate Single Analyte Assay
β-Hydroxybutyrate (BHB, 3-hydroxybutyrate) is an endogenous ketone body that accumulates during periods of fasting, calorie restriction and prolonged exercise. It is created via a multi-step process involving the break-down of fatty acids into acetyl CoA, conversion to acetoacetate and reduction to β-hydroxybutyrate in the liver. BHB is the primary ketone found in the blood and is necessary for brain function especially when glucose is unavailable. It also provides neuroprotective benefits, such as relieving oxidative stress and inhibition of apoptotic pathway in cells.
Bile Acids Targeted Panel
C4 Single Analyte Assay
Central Carbons Targeted Panel
Impaired Glucose Tolerance Targeted Panel
Impaired Glucose Tolerance is a prediabetic state of hyperglycemia that is associated with insulin resistance and an increased risk of cardiovascular pathology (Barr, 2007). The condition occurs when blood glucose levels remain high for an extended period after oral ingestion of glucose but not high enough to be diagnosed as type 2 diabetes.
Impaired Glucose Tolerance can be assessed with a single fasted blood draw by measuring a panel of selected metabolites comprised of two small organic acids (α-hydroxybutyric acid (AHB) and 4-methyl-2-oxopentanoic acid (4MOP)), 2 lipids (oleic acid and linoleoyl glycerophosphocholine (LGPC)), a ketone body (β-hydroxybutyric acid (BHBA)), an amino acid (serine), a vitamin (pantothenic acid (vitamin B5)), and glucose.
Insulin Resistance Targeted Panel
Insulin resistance is a critical pathophysiological state underlying several chronic conditions, including type-2 diabetes, cardiovascular disease (CVD), hypertension, and polycystic ovarian syndrome. Insulin resistance is evident when glucose builds up in the blood stream instead of being absorbed by the body’s cells. It is a result of a diminished response to the hormone insulin at the whole body, organ, or cellular level.
A panel of biomarkers comprised of a small organic acid (α-hydroxybutyric acid (AHB)), 2 lipids (oleic acid and linoleoylglycero-phosphocholine (LGPC)) and insulin identifies insulin resistance with a single fasting blood sample and may have value as an early indicator of risk for the development of prediabetes and type-2 diabetes.
Metal Analysis Targeted Panel
Metabolon in Action
Impact of Probiotic Supplementation on Low Bone Mineral Density (BMD)
Interested in Further Studies?
Once you see the full value of metabolomics, the only remaining question is who does it best? While many laboratories have metabolite profiling or analytical chemistry capabilities, comprehensive metabolomics technologies are extremely rare. Accurate, unbiased metabolite identification across the entire metabolome introduces signal-to-noise challenges that very few labs are equipped to handle. Also, translating massive quantities of data into actionable information is slow, if not impossible, for most because proper interpretation takes two things that are in short supply: experience and a comprehensive database.
Only Metabolon has all four core metabolomics capabilities
Ability to interrogate thousands of metabolites across diverse biochemical space, revealing new insights and opportunities
Ability to integrate the data from different studies into the same dataset, in different geographies, among different patients over time
Ability to inform on proper study design, generate high‐quality data, derive biological insights, and make actionable recommendations
Ability to process hundreds of thousands of samples quickly and cost‐efficiently to service rapidly growing demand
Partner with Metabolon to access:
A library of 5,400+ known metabolites, 2,000 in human plasma, all referenced in the context of biochemical pathways
- That’s 5x the metabolites of the closest competitor
Unparalleled depth and breadth of experience analyzing and interpreting metabolomic data to find meaningful results
- 10,000+ projects with hundreds of clients
- 2,000+ publications covering 500 diseases, including numerous peer-reviewed journals such as Cell, Nature and Science
- Nearly 40 PhDs in data science, molecular biology, and biochemistry
Using our robust platform and visualization tools, our experts are uniquely able to tell you more about your molecule and develop assay panels to help you zero in on the results you need.
Related Precision Medicine Metabolomics Resources
Talk with an expert
Request a quote for our services, get more information on sample types and handling procedures, request a letter of support, or submit a question about how metabolomics can advance your research.
617 Davis Drive, Suite 100
Morrisville, NC 27560
P.O. Box 110407
Research Triangle Park, NC 27709